Paradigm Shift Therapeutics (PSTx) was launched in January 2014 by Teresa Burgess, PhD and Kate Farrell, PhD through an ongoing collaboration with Dr. David Roberts at the National Cancer Institute (NCI) focused on developing CD47-targeting inhibitors-a novel immune-checkpoint target with the potential to radically change treatment for cancer patients.  Thomas Miller PhD joined PSTx as a full partner in September 2014. PSTx's public-private partnership with the National Institutes of Health (NIH) was expanded in September 2015 to launch a drug screening program with the National Center for Accelerating Translational Sciences (NCATS).

PSTx is grateful for ongoing funding from the Avon Foundation for Women and for the business development support from BioHealth Innovation.

While that may sound like a bunch of science jargon that is hard to get your mind wrapped around, you just need to know that PSTx is dedicated to the development of high impact and affordable cancer therapies.



 
Breast Cancer Stakeholders:  YOUR OPINION MATTERS!
Please help PSTx to develop better cancer therapies that maximize patient benefits by participating in a simple survey. Contact Cameron or Sebastian at the email addresses below to set up a quick phone interview.


I did, and I'm glad I did.

Here's to our health...


Life is Good...

Debbie... aka the cancer SURVIVOR, 
AND now the Cardiomyopathy warrior!!!
LIVESTRONG: 

• I AM STRONG • I AM HEALTHY • I AM LOVED •
THANKS for visiting! Comments are good. I look forward to your comments.